Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAOIB + omega-3 fatty acids
- Development stage
- Unknown
- Lead developer
- Chang Gung Memorial Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DAOIB + omega-3 fatty acids is a combination therapy consisting of DAOIB, an NMDA receptor modulator, and omega-3 fatty acids. This combination is being investigated for the treatment of early dementia, specifically amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD). The therapy is hypothesized to improve cognitive function, global functioning, and quality of life in patients with early dementia.
- Other names
- DAOIB + omega-3 fatty acidsNMDA enhancement combined with omega-3 fatty acids
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on DAOIB + omega-3 fatty acids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAOIB + omega-3 fatty acids.